Perspectives: Other ErbB2-Targeted Therapies

Breast care

Ulrike Nitz¹ 

[1] aBrustzentrum Niederrhein, Evangelisches Bethesda-Krankenhaus, Mönchengladbach, Germany

关键词: Neratinib;    Pertuzumab;    Trastuzumab DM-1;    ErbB dimerization inhibitor;    Multifunctional tyrosine;    kinase inhibitors;    ErB2 antibody-drug conjugate therapy;   

DOI  :  10.1159/000285779

学科分类：泌尿医学

来源: S Karger AG

【 摘 要 】

Despite the success of individualized targeted therapies in women with breast cancer with current available compounds, new drugs – especially with different mechanisms of resistance – are under development. A range of novel targeted agents for women with tumors that overexpress ErbB2 (HER2) and progress on trastuzumab and lapatinib have entered clinical studies. Most of these agents are monoclonal antibodies or multifunctional tyrosine kinase inhibitors. Recently published data even showed encouraging synergistic effects of several new substances, which in the future could pose as a chemotherapy-free treatment option in the metastatic setting.

【 授权许可】

Unknown